2016 Hematological Malignancies

GHSG Phase II trial in early-stage favorable HL

cHL in CS I/II without RF* Age 18-75

Strategy B: Replacing Radiotherapy

Strategy A: Reducing Chemotherapy

4 x Bv #

2 x AVD

20 Gy IS-RT

4 x Bv #

*a) large mediastinal mass b) extranodal disease c) elevated ESR d) ≥3 nodal areas # to be discussed: 1.8 mg/kg every 3 weeks or 1.2 mg/kg every 2 weeks

GHSG – December 17, 2013